Pramipexole is used to treat symptoms of Parkinson's disease, such as tremors and stiffness, and is also used to treat restless leg syndrome, a condition that causes uncomfortable sensations in the legs and an irresistible urge to move them.[2] Mirapex is currently approved and in use across 16 indications[4].[1]
Mirapex is one of 306 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
120 competitors in Major Depressive Disorder
Mirapex
Seroquel
Ketalar
Sunosi
Clozaril
Lithobid
Psilocybin
Esketamine Hydrochloride
Aticaprant
Selective Serotonin Reuptake Inhibitor
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jul 1, 1997
MIRAPEX
NDA NDA020667
Feb 19, 2010
MIRAPEX ER
NDA NDA022421
Sources
Details